[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics. CA: a cancer journal for clinicians. 2015;65:87-108.
[2] Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Annals of surgical oncology. 2010;17:194-205.
[3] Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. Jama. 2016;315:1844-53.
[4] Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Annals of oncology. 2008;19:1592-9.
[5] Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. Journal of Clinical Oncology. 2007;25:326-31.
[6] Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. Journal of Clinical Oncology. 2011;29:4105-12.
[7] Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. The lancet oncology. 2013;14:317-26.
[8] Klaassen D, MacIntyre J, Catton G, Engstrom P, Moertel C. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology. 1985;3:373-8.
[9] Group GTS. Treatment of Locally Unresectable Carcinoma of the Pancreas: Comparison of Combined-Modality Therapy (Chemotheraphy Plus Radiotherapy) to Chemotheraphy Alone1. Journal of the National Cancer Institute. 1988;80:751-5.
[10] Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. Journal of Clinical Oncology. 2015;33(16):1770-8.
[11] Matsui Y, Asano T, Kenmochi T, Iwakawa M, Imai T, Ochiai T. Effects of carbon-ion beams on human pancreatic cancer cell lines that differ in genetic status. American journal of clinical oncology. 2005;27:24-8.
[12] Oonishi K, Cui X, Hirakawa H, Fujimori A, Kamijo T, Yamada S, et al. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiotherapy and Oncology. 2012;105:258-65.
[13] Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, et al. Pancreatic tumors show high levels of hypoxia. International Journal of Radiation Oncology Biology Physics. 2000;48:919-22.
[14] Shinoto M, Yamada S, Terashima K, Yasuda S, Shioyama Y, Honda H, et al. Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics. 2016;95:498-504.
[15] Krämer M, Scholz M. Rapid calculation of biological effects in ion radiotherapy. Physics in Medicine & Biology. 2006;51:1959.
[16] Scholz M, Kellerer A, Kraft-Weyrather W, Kraft G. Computation of cell survival in heavy ion beams for therapy. Radiation and environmental biophysics. 1997;36:59-66.
[17] Shinoto M, Shioyama Y, Matsunobu A, Okamoto K, Suefuji H, Toyama S, et al. Dosimetric analysis of upper gastrointestinal ulcer after carbon-ion radiotherapy for pancreatic cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016; 0120:140-4.
[18] Kanai T, Endo M, Minohara S, Miyahara N, Koyama-Ito H, Tomura H, et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. International Journal of Radiation Oncology Biology Physics. 1999;44:201-10.
[19] Kase Y, Kanai T, Matsufuji N, Furusawa Y, Elsässer T, Scholz M. Biophysical calculation of cell survival probabilities using amorphous track structure models for heavy-ion irradiation. Physics in Medicine & Biology. 2007;53:37.
[20] Ghia AJ, Guha-Thakurta N, Hess K, Yang JN, Settle SH, Sharpe HJ, et al. Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously unirradiated metastatic epidural spinal cord compression. International Journal of Radiation Oncology Biology Physics. 2018;102(5):1481-1488.
[21] Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. The Lancet Oncology. 2015;16:187-99.
[22] Durante M, Tommasino F, Yamada S. Modeling combined chemotherapy and particle therapy for locally advanced pancreatic cancer. Frontiers in oncology. 2015;5:145.
[23] Fossati P, Molinelli S, Matsufuji N, Ciocca M, Mirandola A, Mairani A, et al. Dose prescription in carbon ion radiotherapy: a planning study to compare NIRS and LEM approaches with a clinically-oriented strategy. Physics in medicine and biology. 2012;57:7543.
[24] Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. Journal of clinical oncology. 2006;24:4426-33.
[25] Desai SP, Ben-Josef E, Normolle DP, Francis IR, Greenson JK, Simeone DM, et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. Journal of Clinical Oncology. 2007;25:4587-92.